NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$15.67
+0.47 (+3.09%)
Open$15.53
Previous Close$15.20
Day High$16.20
Day Low$15.04
52W High$28.25
52W Low$7.95
Volume—
Avg Volume8.50M
Market Cap2.19B
P/E Ratio—
EPS$-3.53
SectorBiotechnology
Analyst Ratings
Hold
28 analysts
Price Target
+107.5% upside
Current
$15.67
$15.67
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 91.63M | 83.99M | 223.20M |
| Net Income | -558,808,175 | -461,020,586 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -583,901,715 | -508,485,314 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |